CD28 and myocardial infarction: Animals were randomly allocated to treatment with a single dose of the ligand binding inhibiting anti-CD28 mAb E18 or a mAb of the same isotpye (IgG2b), but irrelevant specificity, on day two after myocardial infarction (MI).